Despite complete resection of tumor and mediastinal lymph node dissection, the post-operative survival rate of early stage Ⅰ non-small cell carcinoma is not so good due to increased recurrences. So, we tried to use one of the chemotherapeutic
agents
after complete resection of lung carcinoma even though the pathologic final diagnosis is stage ⅠA or ⅠB in order to improve post-operative survivals.
One-hundred and eight male and 23 female patients (mean age: 62 years, range: 28~83 years) participated in this clinical study from January 1992 to April 2002 at the Department of Thoracic and Cardiovascular Surgery, Yongdong Severance Hospital,
Yonsei
University, College of Medicine, Seoul, Korea.
Twenty-nine patients were in stage ⅠA and 102 were in stage ⅠB. Among them, 3 patients died from surgical problems and 3 patients died from non surgical problems.
Fifty-six patients were placed in the UFT treated group and 61 patients were in the control group. The 5-year survival rate of the patients treated with UFT was 88.6% and the 5-year survival rate of the patients in control group was 72.3%
(p=0.0596).
The results of our trial indicate that even patients with stage ⅠA and ⅠB non-small cell lung carcinoma would be benefited from orall UFT after complete surgical resection of the tumor.
|